TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06437912
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
Study: NCT04169074
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
Study: NCT04830124
Drug: Nemvaleukin Alfa Subcutaneous
Normalized name: Darbepoetin Alfa
DrugBank: Nemvaleukin alfa (DB18187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of nemvaleukin every 7 days
Study: NCT04830124
Drug: Nemvaleukin Alfa Intravenous
Normalized name: Darbepoetin Alfa
DrugBank: Nemvaleukin alfa (DB18187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
Study: NCT04830124
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Normalized name: Nemvaleukin alfa
DrugBank: Nemvaleukin alfa (DB18187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
Study: NCT04830124
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
Study: NCT04700514
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
Study: NCT04759365
Drug: ASN51
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASN51 formulation for oral capsule
Study: NCT00000735
Drug: Ampligen
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05913102
Drug: PDLLA
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer PDLLA/saline every 2 weeks for 2.5 months
Study: NCT06507475
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
Study: NCT05491421
Drug: ZT002
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings
Study: NCT06613841
Drug: Fluciclovine F18
Normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
Study: NCT04409795
Drug: Metformin Extended Release Oral Tablet
Normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial oral hypoglycemic agent added to existing insulin treatment
Study: NCT04409795
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
Study: NCT06112340
Drug: linsitinib
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication taken twice daily by mouth
Study: NCT05382286
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT05382286
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05382286
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05382286
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05382286
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05382286
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT00001996
Drug: Atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001996
Drug: Pentamidine isethionate
Normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06004050
Drug: Delgocitinib
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Topical administration
Study: NCT04709770
Drug: 2-liters polyethylene glycol with citrate and simethicone
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
Study: NCT04709770
Drug: 4-liters polyethylene glycol with simethicone
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
Study: NCT05649163
Drug: Disitamab Vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
Study: NCT05900427
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
Study: NCT05900427
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
Study: NCT04991480
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
Study: NCT04991480
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
Study: NCT05508061
Drug: Insulin Lispro Cartridge [Lyumjev]
Normalized name: insulin lispro Cartridge [Lyumjev]
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of Lyumjev in combination with the AP system
Study: NCT05508061
Drug: Insulin Lispro Cartridge
Normalized name: insulin lispro Cartridge
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of Humalog in combination with the AP system (standard therapy)
Study: NCT06087978
Drug: 14C RPT193
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Radiolabelled RPT193
Study: NCT06192979
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice.
Study: NCT06192979
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
Study: NCT06192979
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients received 20-40 mg oral or intravenous dexamethasone
Study: NCT06192979
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients received venetoclax 400mg daily.
Study: NCT05546619
Drug: HIPEC+tislelizumab + targeted therapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
Study: NCT05430620
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
Study: NCT05848765
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibody
Study: NCT05848765
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunomodulatory agent
Study: NCT05848765
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody
Study: NCT05848765
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody
Study: NCT05848765
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent (chemotherapy drug)
Study: NCT05848765
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplastic, Vinca Alkaloid
Study: NCT05926427
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
Study: NCT05926427
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Study: NCT05848765
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid
Study: NCT05925894
Drug: Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma
Normalized name: Betagen brand of Betamethasone and Gentamicin
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
Study: NCT04845217
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
Study: NCT05953012
Drug: PMC-403
Normalized name: PMC-403
DrugBank: PMC-403 (DB18132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMC-403 will be administered Intravitreal.
Study: NCT04845217
Drug: Coconut Oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated coconut oil taken by mouth three times daily for 8 weeks
Study: NCT05620784
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg of IV furosemide injection during the morcellation phase of HoLEP
Study: NCT05485883
Drug: Tislelizumab Lenvatinib
Normalized name: Tislelizumab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
Study: NCT04485260
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered by mouth
Study: NCT06164288
Drug: Human Amniotic Epithelial Stem Cell Injection
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients.
Study: NCT04764344
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
Study: NCT04764344
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron
Study: NCT06508242
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholecalciferol
Study: NCT03226626
Drug: Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD
Normalized name: bacitracin / polymyxin B / pramoxine hydrochloride Topical Ointment [Betadine Plus Antibiotic and Pain Reliever]
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
Study: NCT04992559
Drug: Consolidation Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
Study: NCT05291390
Drug: Pyronaridine Tetraphosphate
Normalized name: Pyronaridine tetraphosphate
DrugBank: Pyronaridine (DB12975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Via oral capsules.
Study: NCT06140771
Drug: 0.76% Sodium Monofluorophosphate Dentifrice
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT06140771
Drug: 1.15% Sodium Monofluorophosphate Dentifrice
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT06140771
Drug: 0.454% Stannous Fluoride Dentifrice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT05011487
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/qd oral for 60 days
Study: NCT05011487
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
Study: NCT05011487
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
Study: NCT05957887
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
Study: NCT05210595
Drug: Clopidogrel 75 mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg/day as maintenance dose.
Study: NCT05210595
Drug: Ticagrelor 60mg
Normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
Study: NCT05210595
Drug: Ticagrelor 45 mg
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
Study: NCT06156527
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240mg, QD, daily
Study: NCT06156527
Drug: Bevacizumab Injectable Product
Normalized name: bevacizumab Injectable Product
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab: 15mg/kg IV every 3 weeks
Study: NCT05511038
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection, 2mg (equivalent to 50 µL solution for injection)
Study: NCT05441059
Drug: Mepolizumab 100 MG
Normalized name: mepolizumab 100 MG
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with mepolizumab for severe asthma
Study: NCT06026995
Drug: RhG-CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inject rhG-CSF 5-10 μg/kg subcutaneously every day
Study: NCT00313976
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 micrograms every other day, subcutaneously for 104 weeks
Study: NCT00313976
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x250 micrograms every other day, subcutaneously for 104 weeks
Study: NCT00116389
Drug: talabostat mesylate tablets
Normalized name: mesylate
DrugBank: Talabostat (DB06182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00116389
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04887389
Drug: Nano Silver Fluoride varnish
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
Study: NCT04887389
Drug: nano-hydroxyapatite varnish
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
Study: NCT04887389
Drug: sodium Fluoride Varnish
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
Study: NCT05998135
Drug: Atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04733963
Drug: Bevacizumab Plus Capecitabine
Normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study: NCT05568550
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
Study: NCT05583149
Drug: ACALABRUTINIB
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, twice daily, timing and dosage per protocol
Study: NCT05583149
Drug: LISOCABTAGENE MARALEUCEL
Normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: via IV timings and dosage per protocol